Immuno-oncology interests and priorities

IN-PART GLOBAL CHALLENGES

Servier is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need. As a leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients.

Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies. With the company's commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

SERVIER moved by you

R&D challenges and priority areas:

Discovery & Early-stage Clinical Focus

- Cancer cell targeting
  - Synthetic lethality
  - Apoptosis
  - Precision oncology
  - Epigenetic regulators
- Immuno-oncology
  - Tumor micro-environment
  - T cell targeting

Late-stage Clinical Focus

- Hematologic tumors (NHL, ALL, AML)
- Solid tumors (GI as a priority)

Modalities

- Small molecules and biologics (mAbs/bispecifics, ADCs)

Out of scope:

Cell therapies, oncolytic viruses, vaccines

Types of collaboration preferred:

Global or Regional in-licensing (priority EU/China/Japan)

Specific opportunities of interest:

- Small Molecules
  - Kinase, PPi, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
  - Targeted delivery: prodrugs/ polymer drug conjugates/ targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
  - Compound Library
- Antibodies
  - Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
  - Novel technology platform for Antibody Hard-to-Drug targets
  - Synthetic antibody libraries
  - ADCs linkage Chemistry/ Conditionally active antibody format
- AI Driven Strategy
  - AI/ML Data-Driven Platform to support Target ID, Lead Generation & Drug Design Prediction methods for Antibody optimization
  - AI/ML for drug repositioning, indication expansion, clinical combinations

SUBMIT OPPORTUNITIES